U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-KSB [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2004 ----------------- [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ------------- ------------- Commission File No. 000-49655 --------- LIPIDVIRO TECH, INC. -------------------- (Name of Small Business Issuer in its Charter) NEVADA 87-0678927 ------ ---------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1338 S. Foothill Dr. #126 Salt Lake City, Utah 84108 -------------------------- (Address of Principal Executive Offices) Registrant's Telephone Number: (801) 583-9900 Not Applicable -------------- (Former name and former address, if changed since last report) Securities Registered under Section 12(b) of the Exchange Act: None. Name of Each Exchange on Which Registered: None. Securities Registered under Section 12(g) of the Exchange Act: $0.001 par value common stock. Check whether the Registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. (1) Yes X No (2) Yes X No --- --- --- --- Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B is not contained in this form, and no disclosure will be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10- KSB or any amendment to this Form 10-KSB. [ ] State Registrant's revenues for its most recent fiscal year: December 31, 2004 - $0. State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of a specified date within the past 60 days. April 13, 2005 - $2,153.11. There are approximately 2,153,112 shares of common voting stock of the Registrant held by non-affiliates. There is no "established trading market" for our Company's securities, so these shares have been arbitrarily valued at par value of $0.001 per share. ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS Not applicable. Check whether the Registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes X No --- --- APPLICABLE ONLY TO CORPORATE ISSUERS State the number of shares outstanding of each of the Registrant's classes of common equity, as of the latest practicable date: April 13, 2005 Common Stock - 10,031,862 DOCUMENTS INCORPORATED BY REFERENCE A description of "Documents Incorporated by Reference" is contained in Part III, Item 13. Transitional Small Business Issuer Format Yes X No --- --- PART I Item 1. Description of Business. ------------------------ Business Development. --------------------- General. -------- LipidViro Tech, Inc. ("our Company" and "we, "our," "us" and words of similar import) was organized under the laws of the State of California on October 19, 1954. In October 2001, we change our domicile from the State of California to Nevada by merging with and into a wholly-owned subsidiary with the same name, with the Nevada entity being the surviving corporation. We changed our name to "LipidViro Tech, Inc." on February 5, 2004. Business Developments Prior to December 31, 2003. ------------------------------------------------- For information about our business development prior to December 31, 2003, see our 10-KSB Annual Report for the year ended December 31, 2003, that was filed with the Securities and Exchange Commission on April 14, 2004, and which is incorporated herein by reference. See Part III, Item 13. Business Developments During the Year Ended December 31, 2004. -------------------------------------------------------------- On January 12, 2004,a Nevada state court conducted a Fairness Hearing and found that the terms and provisions of our Reorganization Agreement and the issuance and exchange of the securities of our Company with LipidViro Tech, Inc., a Utah corporation ("LipidViro-Utah"), were fair to our shareholders, based upon our acceptance of the terms of the Reorganization Agreement and the information concerning our business and finances and LipidViro-Utah's business and finances. Copies of the Petition for Fairness Hearing and the court's Order Granting Petition of Fairness were attached to our 8-KA-1 Current Report dated August 19, 2003, filed with the Securities and Exchange Commission on March 26, 2004, and are incorporated herein by reference. See Part III, Item 13. On May 10, 2004, we introduced our new GEN-3 technology and reported enhanced viral inactivation utilizing the new GEN-3 technology. Business Developments Subsequent to Year Ended December 31, 2004. ----------------------------------------------------------------- On February 1, 2005, we offered a presentation of our Fluid Purification and Cardiovascular platforms. On March 3, 2005, we announced pre-clinical research results which demonstrated the ability to substantially inactivate infectious prion proteins in bovine serum utilizing our proprietary technology. Prion infectivity was reduced in bovine serum below the limit of detection in both cell and Western blot assays, two gold standard assays for prion detection. This research was submitted for presentation at the Meeting of the International Union of Microbiological Societies, San Francisco, July, 2005. See Part II, Item 6, for additional information about these developments. Business. --------- Overview. --------- We are a development-stage biotechnology company engaged in developing drug products, fluid purification processes, and drug production and delivery systems (DPD System). Utilizing our proprietary DPD System, we are currently developing two products for commercialization; therapeutic treatments for Cardiovascular diseases; and processes to inactivate virus, bacteria and prions producing pathogen-free biological products. Risk Factors. ------------- If we are unable to obtain adequate funds, we may not be able to develop and market our potential products. ---------------------------------- For the twelve months ended December 31, 2004, we incurred a net loss of approximately ($248,977), and from inception of exploration stage through December 31, 2004, we have incurred an accumulated deficit of approximately ($394,692). We expect to continue to incur losses for the foreseeable future as we continue funding for pre-clinical research and other activities related to operations, research and development. Should we seek to develop products that require regulatory approval to sell the products, the regulatory process will take a number of years and will require significant amounts of capital. As of December 31, 2004, we had no cash, cash equivalents and short-term investments. We require immediate financing to provide sufficient working capital for our research and development activities for the next year. For these operational and research and development activities, we will require additional capital in amounts that cannot be quantified, but are expected to be significant. We intend to seek capital needed to fund our operations through new collaborations, through pursuit of research and development grants or through public or private equity or debt financings. Additional financing may not be available on terms favorable to us, or at all. If we are unable to obtain financing on acceptable terms, our ability to continue our business as planned will be significantly harmed. Our technology is only in the clinical development stage, may not prove to be safe or effective and may never receive regulatory approval, which would significantly harm our business prospects. ------------------------------------------ Before obtaining required regulatory approvals for the commercial sale of any potential products, we must demonstrate, through pre-clinical studies and clinical trials, that our technology is safe and effective for use in at least one medical indication. These studies and clinical trials are expected to take a number of years and may fail to show that our technology is sufficiently safe and effective, in which case our technology will not receive regulatory approval, and we will not be able to develop and commercialize our products. Our technology, and hence, our business, at present is limited to evaluating the capacity of LVT3 and our proprietary process to inactivate pathogens including virus and prions, and treat different cardiovascular diseases. --------- Accordingly, if our technology does not prove to be safe or effective, or if we otherwise fail to receive regulatory approval for our potential product indications, our business prospects would be significantly harmed and possibly it could cause us to cease operations. Our pre-clinical studies may be delayed or unsuccessful. -------------------------------------------------------- Our future success depends in large part upon the results of pre-clinical studies designed to evaluate the capacity of LVT3 and our proprietary process to inactivate pathogens including virus and prions, and treat different cardiovascular diseases, so that we can select potential products for commercial development. The ultimate results of pre-clinical studies cannot be predicted with accuracy and may be impacted by many variables. We cannot be sure whether planned pre-clinical research will begin on time or will be completed on schedule or at all. Delay or failure to complete pre-clinical studies may delay or prevent us from identifying potential products for commercial development, which would materially harm our business. For example, any of our future clinical studies might be delayed in their initiation or performance, or even halted after initiation because we are unable to secure financing of operations and research. We intend to seek collaborations in order to further develop our products. --------- If we are unsuccessful in attaining these collaborations, the development of our products could be adversely affected and we may incur significant unexpected costs. We intend to seek collaborations with strategic partners, licensors, licensees and others. We may be unable to attain collaborations or licensing arrangements necessary to develop our technology or on favorable terms. Any current or future collaborations or licensing arrangements may not be successful. In addition, parties we collaborate with may develop products that compete with ours, and we cannot be certain that they will perform their contractual obligations or that any revenues will be derived from such arrangements. If we were to enter into a collaboration, one or more of parties in such may fails to achieve product development objectives, this failure could harm our ability to fund related programs and develop or commercialize products. We may not be able to continue in our research facilities. ---------------------------------------------------------- We have outsourced our clinical research to independent laboratory facilities where our primary research is conducted. We may encounter a time when the lab is no longer available to our research, therefore limiting our research until arrangements for other facilities can be negotiated. Furthermore, we may encounter halts and delays related to our research as a result of: * Lengthy approvals required for government regulated materials key to our research that may delays, or may make certain materials unavailable to our outsourced research facilities; * New regulatory requirements for laboratory facilities that may delay our research efforts; * Unforeseen cost overruns; * Other unforeseeable factors that arise from not owning and operating our laboratory facilities; and * Failure to maintain financial obligations with our outsourced laboratory facilities. Our industry is intensely competitive. -------------------------------------- The biotechnology industry is intensely competitive and we may not be able to develop, perfect or acquire rights to new products with commercial potential. We compete with biotechnology and pharmaceutical companies that have been established longer than we have, have a greater number of products on the market, have greater financial and other resources and have other technological or competitive advantages. We also compete in the development of technologies and processes and in acquiring personnel and technology from academic institutions, governmental agencies, and other private and public research organizations. We cannot be certain that one or more of our competitors will not receive patent protection that dominates, blocks or adversely affects our clinical studies, product development or business; will benefit from significantly greater sales and marketing capabilities; or will not develop products that are accepted more widely than ours. If we fail to secure and then enforce patents and other intellectual property rights underlying our technologies, we may be unable to compete effectively. ------------ Our future success will depend in part on our ability to obtain patent protection, defend patents once obtained, maintain trade secrets and operate without infringing upon the patents and proprietary rights of others, and if needed, obtain appropriate licenses to patents or proprietary rights held by third parties with respect to its technology, both in the United States and in foreign countries. We currently have applied for patent protection covering our technology. However, our patent applications may not be approved and, even if approved, our patent rights may not be upheld in a court of law or may be narrowed if challenged. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. Our patent rights may not provide competitive advantages for our products and may be challenged, infringed upon or circumvented by our competitors. In addition to patents, we rely on trade secrets, know-how, continuing technological innovations, and licensing opportunities to develop and maintain our competitive position. It is our policy to require our employees, certain contractors, consultants, members of our scientific and viral advisory boards and parties to collaborative agreements to execute confidentiality agreements upon the commencement of a business relationship with us. We cannot assure you that these agreements will not be breached, that they will provide meaningful protection of our trade secrets or know-how or adequate remedies if there is unauthorized use or disclosure of this information or that our trade secrets or know-how will not otherwise become known or be independently discovered by our competitors. If it were ultimately determined that our intellectual property rights are unenforceable, or that our use of our technology infringes on the intellectual property rights of others, we may be required or may desire to obtain licenses to patents and other intellectual property held by third parties to develop, manufacture and market products using our technology. ------------------------------------------------------------------------- We may not be able to obtain these licenses on commercially reasonable terms, if at all, and any licensed patents or intellectual property that we may obtain may not be valid or enforceable. In addition, the scope of intellectual property protection is subject to scrutiny and challenge by courts and other governmental bodies. Litigation and other proceedings concerning patents and proprietary technologies can be protracted, expensive and distracting to management and companies may sue competitors as a way of delaying the introduction of competitors' products. Any litigation, including any interference proceedings to determine priority of inventions, oppositions to patents in foreign countries or litigation against our partners, may be costly and time-consuming and could significantly harm our business. Because of the large number of patent filings in the biopharmaceutical field, our competitors may have filed applications or been issued patents and may obtain additional patents and proprietary intellectual property rights relating to products or processes competitive with or similar to ours. We cannot be certain that U.S. or foreign patents do not exist or will be issued that would harm our ability to commercialize our products and product candidates. If we use biological and hazardous materials in a manner that causes injury, we may be liable for damages. ------------------------------------- Our research and development activities involve the controlled use of potentially harmful biological materials, such as blood products, organic solvents and other hazardous materials. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could be significant. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations could be significant. Our business exposes us to product liability claims. ---------------------------------------------------- Our design, testing, development, manufacture and marketing of products involve an inherent risk of exposure to product liability claims and related adverse publicity. Insurance coverage is expensive and difficult to obtain, and we may be unable to obtain coverage in the future on acceptable terms, if at all. If we seek insurance and are unable to obtain sufficient insurance at an acceptable cost or if a successful product liability claim is made against us, whether fully covered by insurance or not, our business could be harmed. We depend on key personnel. --------------------------- Our ability to operate successfully depends in significant part upon the experience, abilities and continued service of certain key scientific, technical and managerial personnel. If we lose the services of any of these personnel and we are unable to hire qualified replacements, our business could be harmed. Our future success also depends upon our ability to attract and retain additional highly qualified personnel in these areas and our ability to develop and maintain relationships with qualified clinical researchers. Competition for such personnel and relationships is intense. There can be no assurance that we can retain such personnel or that we can attract or retain other highly qualified scientific, technical and managerial personnel or develop and maintain relationships with clinical researchers in the future. Our stock price may be volatile and there may not be an active trading market for our common stock. ---------------------------- There can be no assurance that there will be an active trading market for our common stock or that the market price of the common stock will not decline below its present market price. The market prices for securities of biotechnology companies have been, and are likely to continue to be, highly volatile. Factors that have had, and are expected to continue to have, a significant impact on the market price of our common stock include: * material public announcements; * actual or potential clinical results with respect to our products under development or those of our competitors; * the announcement and timing of any new product introductions by us or others; * technical innovations or product development by us or our competitors; * regulatory approvals or regulatory issues; * developments relating to patents and proprietary rights; * political developments or proposed legislation in the medical device or healthcare industry; * economic and other external factors, disaster or crisis; * changes to our management; * period-to-period fluctuations in our financial results or results which do not meet or exceed analyst expectations; and * market trends relating to or affecting stock prices throughout our industry, whether or not related to results or news regarding us or our competitors. In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of its securities. We may, in the future, be the target of similar litigation. Regardless of its outcome, securities litigation may result in substantial costs and divert management's attention and resources, which could harm our business and results of operations. Shares eligible for future sale. -------------------------------- The future sale of substantial number of shares of our common stock, or the perception that such sales could occur, would impact the market price of our common stock. The future sale of substantial number of the new shares issued to LipidViro-Utah shareholders, or the exercise and sale of the common stock underlying the A or B warrants or the perception that such sales could occur, would also impact the market price of our common stock. If a substantial number of these newly issued shares of common stock that have become available for sale or will be available for sale in the future are sold, the market price of our common stock may be negatively impacted. It is believed that all of these securities are freely tradable without registration under the Securities Act by reason of their issuance under Section 3(a)(10) thereof. Existing stockholders may experience substantial dilution. ---------------------------------------------------------- In connection with the LipidViro-Utah Reorganization Agreement, we will have to issue additional shares of common stock in the event 1,915,000 "A" warrants and 1,915,000 "B" like warrants are exercised, which will have the effect of diluting the ownership of our stockholders. In addition, we require immediate financing which if funded through equity financings, would further dilute existing stockholders. Principal Products or Services. ------------------------------- We are currently conducting pre-clinical laboratory research focused on the development of drug and biological products that utilize our proprietary process and equipment that produces our lipid targeting, anti-pathogenic investigational compound, LVT3. We currently have no approved, saleable products or services, and accordingly, are considered to be a biotechnology company in the development stage. Distribution Methods. --------------------- None; not applicable. Competitive Business Conditions. -------------------------------- The biotechnology industry is extremely competitive and we may not be able to develop, perfect or acquire rights to new products with commercial potential. We compete with biotechnology and pharmaceutical companies that have been established longer than we have, have a greater number of products on the market, have greater financial and other resources and have other technological or competitive advantages. We also compete in the development of technologies and processes and in acquiring personnel and technology from academic institutions, governmental agencies, and other private and public research organizations. We cannot be certain that one or more of our competitors will not receive patent protection that dominates, blocks or adversely affects our clinical studies, product development or business; will benefit from significantly greater sales and marketing capabilities; or will not develop products that are accepted more widely than ours. Our future success will depend in part on our ability to obtain patent protection, defend patents once obtained, maintain trade secrets and operate without infringing upon the patents and proprietary rights of others, and if needed, obtain appropriate licenses to patents or proprietary rights held by third parties with respect to its technology, both in the United States and in foreign countries. Any future patent rights also may not provide competitive advantages for our products and may be challenged, infringed upon or circumvented by our competitors. In addition to future patents, we rely on trade secrets, know-how, continuing technological innovations, and licensing opportunities to develop and maintain our competitive position. It is our policy to require our employees, certain contractors, consultants, members of our general board and scientific advisory boards and parties to collaborative agreements to execute confidentiality agreements upon the commencement of a business relationship with us. We cannot assure you that these agreements will not be breached, that they will provide meaningful protection of our trade secrets or know-how or adequate remedies if there is unauthorized use or disclosure of this information or that our trade secrets or know-how will not otherwise become known or be independently discovered by our competitors. We will pursue all legal avenues to ensure however that any breach is held accountable by the fullest extent of the law. We can give no assurance that there will be an active trading market for our common stock and warrants or that the market price of the common stock will not decline below its present market price. The market prices for securities of biotechnology companies have been, and are likely to continue to be, highly volatile. Factors that have had, and are expected to continue to have, significant impacts on the market price of our common stock include: * intellectual property developments by us or our competitors; * legislation in the field of biotechnology, medicine or healthcare; * economic, environmental or disasters; * management turnover; * product development by us or our competitors; * technical innovations by us or our competitors; * regulatory issues or approvals; * financial and analyst expectations; * market trends relating to or affecting stock prices; * press releases; * clinical results under development or those of our competitors; and * new products announced by us or our competitors. Patents, Trademarks, Licenses, Franchises, Concessions, Royalty Agreements or Labor Contracts. ---------------- We have filed for patent protection in the U.S. and abroad seeking protection of our lipid targeting, anti-pathogenic equipment, devices, processes, potential products and compounds. To date we have not been issued or denied patent protection on our patent applications. Where necessary, we may attempt to obtain rights to various patents and patent applications under licenses with third parties that provide for the payment of royalties by us. The ultimate degree of patent protection that will be afforded to biotechnology products and processes, including ours, in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. There is no certainty that our existing patent applications or others we may apply for, if issued, will afford us substantial protection or commercial benefit. Similarly, there is no assurance that our pending patent applications or any potential patent applications licensed from third parties will ultimately be granted as patents or that those patents that have been issued or are issued in the future will prevail if they are challenged in court. There has been, and we expect that there may continue to be, significant litigation in the industry regarding patents and other intellectual property rights. Intellectual property litigation could therefore create business uncertainty and consume substantial financial and human resources. In general, we might attempt to obtain licenses to third party patents that we deem necessary or desirable for the manufacture, use and sale of any products we may develop or attempt to develop. There is considerable uncertainty within the biotechnology industry about the validity, scope and enforceability of many issued patents in the U.S. and elsewhere in the world, and, to date, there is no consistent policy regarding the breadth of claims allowed in biotechnology patents. Need for Governmental Approval of Principal Products or Services. ----------------------------------------------------------------- The process of obtaining requisite United States Federal Drug Administration ("FDA") approval has historically been costly and time consuming. Current FDA requirements for a new human drug or biological product to be marketed in the United States include: (1) the successful conclusion of pre-clinical laboratory and animal tests, if appropriate, to gain preliminary information on the product's safety; (2) filing with the FDA of an Investigational New Drug Application, commonly known as an INDA, to conduct human clinical trials for drugs or biologics; (3) the successful completion of adequate and well-controlled human clinical investigations to establish the safety and efficacy of the product for its recommended use; and (4) filing by a company and acceptance and approval by the FDA of a New Drug Application ("NDA") for a drug product or a Biological License Application ("BLA") for a biological product to allow commercial distribution of the drug or biologic. Pre-clinical tests include the evaluation of the product in the laboratory and in animal studies to assess the potential safety and efficacy of the product and its formulation. The results of the pre-clinical tests are submitted to the FDA as part of an INDA to support the evaluation of the product in human subjects or patients. Clinical trials involve administration of the product to patients under supervision of a qualified principal investigator. Such trials are typically conducted in four sequential Phases, although the Phases may overlap. In Phase I, the initial introduction of the drug into human subjects, the product is tested for safety, dosage tolerance, absorption, metabolism, distribution, and excretion. Phase II involves studies in a limited patient population to: (1) determine the biological or clinical activity of the product for specific, targeted indications; (2) determine dosage tolerance and optimal dosage; and (3) identify possible adverse effects and safety risks. If Phase II evaluations indicate that a product is effective and has an acceptable benefit-to-risk relationship, Phase III trials may be undertaken to further evaluate clinical efficacy and to further test for safety within an expanded patient population. Phase IV studies, or post-marketing studies, may also be required to provide additional data on safety or efficacy. The FDA reviews the results of the clinical trials and may order the temporary or permanent discontinuation of clinical trials at any time if it believes the product candidate exposes clinical subjects to an unacceptable health risk. Investigational products used in clinical studies must be produced in compliance with cGMP pursuant to FDA regulations. On November 21, 1997, President Clinton signed into law the Food and Drug Administration Modernization Act. That Act codified the FDA's policy of granting "fast track" approval for cancer therapies and other therapies intended to treat serious or life threatening diseases and that demonstrate the potential to address unmet medical needs. The fast track program emphasizes close, early communications between FDA and the sponsor to improve the efficiency of pre-clinical and clinical development, and to reach agreement on the design of the major clinical efficacy studies that will be needed to support approval. Under the fast track program, a sponsor also has the option to submit and receive review of parts of the NDA or BLA on a rolling schedule approved by FDA, which expedites the review process. The FDA's Guidelines for Industry Fast Track Development Programs require that a clinical development program must continue to meet the criteria for Fast Track designation for an application to be reviewed under the Fast Track Program. Previously, the FDA approved cancer therapies primarily based on patient survival rates or data on improved quality of life. While the FDA could consider evidence of partial tumor shrinkage, which is often part of the data relied on for approval, such information alone was usually insufficient to warrant approval of a cancer therapy, except in limited situations. Under the FDA's new policy, which became effective on February 19, 1998, fast track designation ordinarily allows a product to be considered for accelerated approval through the use of surrogate endpoints to demonstrate effectiveness. As a result of these provisions, the FDA has broadened authority to consider evidence of partial tumor shrinkage or other surrogate endpoints of clinical benefit for approval. This new policy is intended to facilitate the study of cancer therapies and shorten the total time for marketing approvals. Under accelerated approval, the manufacturer must continue with the clinical testing of the product after marketing approval to validate that the surrogate endpoint did predict meaningful clinical benefit. We intend to take advantage of the fast track programs; however, it is too early to tell what effect, if any, these provisions may have on the approval of our product candidates. The orphan drug provisions of the Federal Food, Drug, and Cosmetic Act provide incentives to drug and biologics manufacturers to develop and manufacture drugs for the treatment of rare diseases, currently defined as diseases that exist in fewer than 200,000 individuals in the U.S. or, for a disease that affects more than 200,000 individuals in the U.S., where the sponsor does not realistically anticipate that its product will become profitable. Under these provisions, a manufacturer of a designated orphan product can seek tax benefits, and the holder of the first FDA approval of a designated orphan product will be granted a seven-year period of marketing exclusivity for that product for the orphan indication. While the marketing exclusivity of an orphan drug would prevent other sponsors from obtaining approval of the same compound for the same indication, it would not prevent other types of drugs from being approved for the same indication. We plan on performing pre-clinical research of a variety of viral and bacterial and infectious protein (prion) pathogens that typically affect humans and biological fluids. Should the compounds and substances targeted by our Company show efficacy during initial in-vitro study, our Company may seek "Fast Track" and Orphan Drug status designation to secure expedited review. It is uncertain whether we will obtain fast track designation. We cannot predict the ultimate effect, if any, of the new fast track process on the timing or likelihood of FDA approval of any as yet unknown products. Effect of Existing or Probable Governmental Regulations on the Business. ----------------------------------------------------------------------- General. -------- Drugs, devices and biologic products must satisfy rigorous standards of safety and effectiveness before they can be approved or, in the case of some medical devices, "cleared" for commercial marketing by the Food and Drug Administration, or the FDA. The FDA has extensive power and discretion over this approval process, subject to the provisions of its governing statutes, which consist principally of the Federal Food, Drug, and Cosmetic Act with respect to pharmaceuticals and medical devices, and the Public Health Service Act in the case of drug or device products of a biological nature, such as processed plasma. The FDA also has promulgated detailed regulations to implement these statutes and has issued various non-binding guidance documents to advise industry on matters in more detail on statutory and regulatory requirements. In evaluating the regulatory status of any proposed product, many different factors are involved and, thus, there may be additional statutory/ regulatory provisions or requirements that are unique to a particular product that are not included in this general discussion. In defining a product's regulatory status, several key factors must be considered such as, but not limited to: * the product's intended use as derived from proposed labeling; * its primary mode of action; * whether the active ingredient is derived from chemical synthesis, which normally is regulated as a drug under the Federal Food, Drug, and Cosmetic Act, or is a product derived from biotechnology, such as recombinant DNA, or human, animal or plant sources, in which case it commonly, but not always, is regulated as a biologic under the Public Health Service Act and a biological drug under the Federal Food, Drug, and Cosmetic Act; * whether it is a virus, therapeutic serum, antitoxin, vaccine, blood, blood component, blood derivative, allergenic product, or analogous product or other very specific products, in which case it is regulated under the Public Health Service Act as a biologic and, if applicable, under the Federal Food, Drug, and Cosmetic Act, as a biological drug; and * the FDA's prior handling of similar products, which has, in a number of cases, treated products differently than would appear to be required under a reading of applicable statutes. The extent and nature of the FDA regulatory requirements also will depend on the labeled uses, or indications, for which approval is sought and the type, complexity and novelty of the product. In the case of medical devices, the Federal Food, Drug, and Cosmetic Act requires that the most risky products, referred to as Class III devices, be the subject of a pre-market approval application under Section 515 of the Federal Food, Drug, and Cosmetic Act. A pre-market approval application usually requires that the applicant conduct well-controlled clinical studies to demonstrate the safety and effectiveness of its medical device. Other medical devices can be cleared for marketing by the FDA pursuant to what is known as a pre-market notification. Clearance of a pre-market notification filing relies on a finding by the FDA that the applicant's device is substantially equivalent to a lawfully marketed device that itself does not require a pre-market approval application. And, in the case of other even less risky devices, the FDA has eliminated the need to file a pre-market notification at all, although the product and its maker generally are still subject to the other general controls contained in the Federal Food, Drug, and Cosmetic Act and the device regulations. The part of the FDA having primary jurisdiction over medical devices is the Center for Devices and Radiological Health, or Devices Center. Drug products and biological drug products whose active ingredients have never been approved by the FDA or which, although having the same ingredient, differ in a substantial way from an approved product usually will require the applicant to file a full new drug application containing substantial evidence in the form of well-controlled clinical investigations that the drug product or biological drug product is safe and effective for its labeled indication(s). In contrast, a generic version of a previously approved drug product may be approved by the FDA under an "abbreviated" new drug application in which the showing of safety and effectiveness is satisfied by the applicant proving that its drug is bioequivalent to the drug product originally approved under a full new drug application that forms the basis for the abbreviated new drug application. To qualify for the abbreviated new drug application process, a generic drug, with some limited exceptions, must be identical to that of the drug covered under the full new drug application as to active ingredient, labeling, dosage strength, dosage form, and route of administration. The part of the FDA having primary jurisdiction over drugs is the Center for Drug Evaluation and Research, or Drugs Center, and over biological drugs is the Center for Biologics Evaluation and Research, or Biologics Center. Biologics are regulated under the Public Health Service Act, which prohibits marketing them without an approved license from FDA known as a Biologics License Application. Biologics regulation, under the Public Health Service Act, also focuses on whether a biologic is pure, safe and potent. Biologics License Applications for therapeutic biological drug products are similar to new drug applications and well-controlled clinical investigations to show safety and effectiveness are often required. The regulation of biologics also is impacted by the fact that biologics may be used in conjunction with a medical device such as a diagnostic kit. If used in conjunction with a device, the biologic product must satisfy the Public Health Service Act requirements and also may need to go through the pre-market approval application procedure, which may require that the applicant conduct clinical studies to secure approval. There is no mechanism existing today that provides for a Biologics License Application for a "generic" biologic drug. If the FDA grants marketing approval of a product, this approval will be limited to those disease states and conditions for which the product has been demonstrated to be safe and effective. Any product approval also could include significant restrictions on the use or marketing of a firm's products or include other conditions, such as the performance of post-approval studies to monitor known or suspected adverse reactions. Product approvals, if granted, are subject to potential withdrawal, either voluntarily or involuntarily through legal process, for failure to comply with regulatory requirements or upon the occurrence of adverse events following commercial introduction of the products. Regulatory Status of Our Products. ---------------------------------- Due to the early nature of our development efforts, we have not yet confirmed with the FDA its view of the regulatory status of any of our potential products or which center of the FDA might have primary responsibility for review of our regulatory submissions. Depending on the claims made and the FDA's ruling regarding the regulatory status of our products, they may be designated as devices, biologics or as combination products. However, we anticipate that regardless of regulatory designation, we will need to conduct pre-clinical and clinical studies to prove the safety and effectiveness of all potential products we may attempt to commercially develop. To support a regulatory submission, the FDA commonly requires clinical studies to show safety and effectiveness. While we cannot currently state the nature of any such studies that the FDA may require due to our early stage of product research, it is likely any product we attempt to develop will require extensive and time-consuming clinical studies in order to secure approval. If we come to a point where we have selected specific products for commercial development in the United States, once we have sufficient information to design our pre-clinical and clinical development plans, we will seek the FDA's input on those plans and, more specifically, the agency's requirements for approval. However, the FDA may insist upon changes to a development plan previously agreed to by the FDA if new information shows that the plan may present safety or effectiveness concerns. The FDA also retains considerable leverage to require changes in study protocols from the sponsors of clinical investigations even after an FDA meeting and agreement has been reached. A meeting with the FDA to establish the pre-clinical and clinical protocols to support a pre-market approval application will be a critical step in the development of most products we anticipate developing. For medical devices, such a meeting commonly is held at what is known as the pre- investigational device exemption stage. For a drug or biologic product, such a meeting commonly is held at what is known as the pre-investigational new drug stage. Outside the United States, the ability to market potential products is contingent upon receiving market application authorizations from the appropriate regulatory authorities. These foreign regulatory approval processes may involve differing requirements than those of the FDA, but also generally include many, if not all, of the risks associated with the FDA approval process described above, depending on the country involved. Clinical Studies - General. --------------------------- Assuming we are able to select a product for commercial development, depending on the regulatory status of a potential product, we will likely need to conduct significant additional research before we can file applications for product approval. Typically, in the drug, device, and biologics industries there is a high rate of attrition for product candidates in pre-clinical testing and clinical trials. Success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful. For example, a number of companies in the drug industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after promising results in earlier trials and in interim analyses. In addition, delays or rejections may be encountered based upon additional government regulation, including any changes in the FDA policy during the process of clinical trials. In order to conduct clinical investigations on a new drug product, for example, whether of chemical or biological origin, that have not been previously approved in the United States or have not been approved for the labeled indication being sought by an applicant, the applicant or sponsor must first file an investigational new drug (IND) application with the FDA. Such application must contain, among other things, detailed information on the proposed drug product, the contemplated protocol for conducting the clinical investigation, and any available safety and effectiveness information on the proposed drug product. In addition, an Institutional Review Board must approve the protocol to ensure that it provides adequate protection of the rights of the human subjects to be included in the clinical study. If the FDA does not object to the IND application, the study may begin after 30 days from the date the IND application was filed. The FDA may affirmatively approve the IND application prior to the expiration of the 30-day period, at which point the clinical study may begin. If human clinical trials of a device are required for a pre-market approval application and if the device presents a significant risk as defined in the FDA's regulations, the sponsor of the trial (usually the manufacturer or the distributor of the device) must submit an investigational device exemption (IDE) filing prior to commencing human clinical trials. The IDE application must be supported by data, typically including the results of animal and laboratory testing and include the proposed protocol governing the clinical study. If the IDE application is approved by the FDA and an appropriate Institutional Review Board, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. Submission of an IDE application or IND application does not give assurance that the FDA will not object to the IDE application or IND application. Furthermore, even if the IDE application or IND application becomes effective, there can be no assurance that the FDA will determine that the data derived from the studies support the safety and efficacy of the drug or device or warrant the continuation of clinical studies. In addition, the regulations governing INDs and IDEs are extensive and involve numerous other requirements including that, generally, an IDE application or IND application supplement must be submitted to and approved by the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness or the rights, safety or welfare of human subjects. Deviation from these regulatory requirements can lead to the FDA refusing to consider the study in support of a commercial marketing application. In some circumstances, sponsors of clinical trials are permitted to sell investigational drugs, biologics, or devices distributed in the course of the study, provided such compensation does not exceed recovery of the costs of manufacture, research, development and handling. If we elect to pursue this option, we will need to seek the FDA's approval if the clinical investigation is conducted under an investigational new drug or an investigational device exemption. The FDA routinely does not grant such approvals. Typically, a showing of special need is required. Reporting Requirements. ----------------------- As an issuer whose securities are registered under Section 12(g) of the Securities Exchange Act of 1934 (the "Exchange Act"), we are required to file periodic reports with the Securities and Exchange Commission. In addition, the National Association of Securities Dealers, Inc. (the "NASD"), requires that all issuers maintaining quotations of their securities on the OTC Bulletin Board file periodic reports under the Exchange Act, so if we apply for a trading symbol on the OTC Bulletin Board, the NASD will also require that we remain current in our reporting obligations. The public may read and copy any materials that we file with the Securities and Exchange Commission at the Securities and Exchange Commission's Public Reference Room at 450 Fifth Street N.W., Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the Securities and Exchange Commission at 1-800-SEC-0330 or 1-202-942- 8090. The securities and Exchange Commission maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the Securities and Exchange Commission. The address of that site is http://www.sec.gov. Small Business Issuer. ---------------------- The Securities and Exchange Commission's integrated disclosure system for small business issuers, which was adopted in Release No. 34-30968 and became effective as of August 13, 1992, substantially modified the information and financial requirements of a "Small Business Issuer," defined to be an issuer that has revenues of less than $25,000,000; is a U.S. or Canadian issuer; is not an investment company; and if a majority-owned subsidiary, the parent is also a small business issuer; provided, however, an entity is not a small business issuer if it has a public float (the aggregate market value of the issuer's outstanding securities held by non-affiliates) of $25,000,000 or more. Sarbanes-Oxley Act. ------------------- On July 30, 2002, President Bush signed into law the Sarbanes-Oxley Act of 2002. The Sarbanes-Oxley Act imposes a wide variety of new regulatory requirements on publicly-held companies and their insiders. Many of these requirements will affect us. For example: * Our chief executive officer and chief financial officer must now certify the accuracy of all of our periodic reports that contain financial statements; * Our periodic reports must disclose our conclusions about the effectiveness of our disclosure controls and procedures; and * We may not make any loan to any director or executive officer and we may not materially modify any existing loans. The Sarbanes-Oxley Act has required us to review our current procedures and policies to determine whether they comply with the Sarbanes-Oxley Act and the new regulations promulgated thereunder. We will continue to monitor our compliance with all future regulations that are adopted under the Sarbanes- Oxley Act and will take whatever actions are necessary to ensure that we are in compliance. Estimate of Amount Spent on Research and Development Activities. ---------------------------------------------------------------- We spent $175,902 in research and development costs during the period from January 1, 2004 through December 31, 2004, through LipidViro-Utah. Costs and Effects of Compliance with Environmental Laws. -------------------------------------------------------- None, not applicable. Total Number of Employees and Number of Full-Time Employees. ------------------------------------------------------------ As a development stage company, our business strategy for research, product development and operational management relies on maintaining low overhead by outsourced professional services for legal, accounting, laboratory personnel including virology, cell biology, chemistry, laboratory equipment and facilities, equipment manufacturing personnel and facilities, and, business and scientific consulting. We have outsourced our clinical research to independent laboratory facilities in which our primary pre-clinical research is conducted. These laboratory facilities have available, and include equipment and laboratory personnel necessary to conduct our anticipated pre-clinical research during the fiscal year 2005. We have negotiated a one-year agreement for the use of these research facilities, associated staff and a research coordinator to conduct these activities. The new research agreement signed August 19, 2004, allows us to pay up to $600,000 for supplies, facilities, a laboratory technician and coordination efforts running through the end of fiscal year 2005; the overall project design will be oriented toward investigations that may lead to a potential in vitro, ex vivo or in vivo process, drug or other therapeutic modality that resides within the proprietary scope of our patented technology. Whenever possible, we have utilized unpaid consultants to perform certain functions of our business, including (but not limited to): business development, product development, strategic planning, corporate structuring, patent and intellectual property strategies, research, drug development and, equipment development. No cash, stock or compensation of any kind has been paid or promised to any unpaid consultant. During the fiscal year 2005, we expect to continue to utilize unpaid consultants whenever possible to maintain low overhead expenses. In the event there are no unpaid consultants available to assists us, we are able to manage all operational aspects of the Company without the assistance of any such unpaid consultants. As of December 31, 2004, no board member or officer has received any cash compensation from us. Once we are better capitalized, we plan on creating a compensation plan with benefits, intended to assist in attracting and retaining qualified officers and personnel. We believe the success of our business will depend, in significant part, on our ability to attract and retain such personnel. Offices, Research Facilities. ----------------------------- We own no real estate and do not lease office space for management and administrative functions. All administrative functions are conducted from home-based offices located in the homes of the officers and employees of the company. We have not had a need to rent office space, and we have no anticipated need to lease office space for administrative and managerial functions. We expect to continue the practice of conducting all administrative and managerial functions from the home-based offices of officers and employees of ours for fiscal year 2005. There is no expense to us for these home based offices, other than incidental offices supplies. At some point, we may require additional office space requiring rental expense, but we do not anticipate any such need during fiscal year 2005. We have outsourced our clinical research to independent laboratory facilities in which our primary pre-clinical research is conducted. These laboratory facilities have available, and include equipment and laboratory personnel necessary to conduct our anticipated pre-clinical research during the fiscal year 2005. We have negotiated a one-year agreement for the use of these research facilities, associated staff and a research coordinator to conduct these activities. The new research agreement signed August 19, 2004 allows the Company to pay up to $600,000 for supplies, facilities, a laboratory technician and coordination efforts running through the end of fiscal year 2005; the overall project design will be oriented toward investigations that may lead to a potential in vitro, ex vivo or in vivo process, drug or other therapeutic modality that resides within the proprietary scope of our patented technology. Item 2. Description of Property. ------------------------ We own no office space, research facilities or real estate; we have no need or anticipated need to lease office space or any real estate to conduct our operations in the near future or during fiscal 2005. We have outsourced our research by contracting independent research facilities to conduct our research, negating the need to rent or lease research facilities and research equipment. We conduct all administrative and managerial functions from the home-based offices of officers and employees of ours. At some point in the future, we may require additional office space and our own research facilities that would necessitate rental or lease expenses. We do not anticipate any such need for these offices or research facilities during fiscal year 2005. (See the heading "Offices, Research Facilities," above) Item 3. Legal Proceedings. ------------------ We are not the subject of any pending legal proceedings and, to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. On December 1, 2004, the Third Judicial District Court of Salt Lake County, State of Utah, Ordered, Adjudged and Decreed that our Motion for Partial Summary Judgment be granted against Natt Bottomley, Ross Bottomley, Jeff Pace, Advocates for Medizone and Does 1-20. Natt Bottomley, along with other defendants named in this action, engaged in several unlawful activities in an attempt to harm LipidViro-Utah by violating provisions of a Non-Disclosure, Non-Compete Agreement, including: defaming LipidViro-Utah, intentionally interfering with its present and prospective economic relations, misappropriating trade secrets and engaging in conspiratorial activities to irreparably harm LipidViro-Utah's business. We were originally granted a TRO on August 20, 2003, and a Preliminary Injunction against the defendants on December 9, 2003. Defendant Natt Bottomley was restrained and enjoined from committing any further violations of the Confidentiality and Non-Compete Agreement between Natt Bottomley and LipidViro-Utah; Defendants Advocates for Medizone, Natt Bottomley, Ross Bottomley, Jeff Pace, were restrained and enjoined from using and/or disclosing any of LipidViro-Utah's confidential or proprietary information; Defendants were restrained and enjoined from making any defamatory statements to any persons regarding LipidViro-Utah and/or persons associated with LipidViro-Utah; Defendants were restrained and enjoined from taking any actions to interfere with the economic relationships of LipidViro-Utah; and Defendants were restrained and enjoined from contacting any of LipidViro-Utah's business associates and/or vendors, including, but not limited to the National Institute of Health. Item 4. Submission of Matters to a Vote of Security Holders. ---------------------------------------------------- No matter was submitted to a vote of our security holders during the calendar year covered by this Annual Report or during the two previous calendar years, however, we did file an Information Statement that was mailed to our shareholders on July 23, 2003, and filed with the Securities and Exchange Commission on July 23, 2003, that notified our shareholders that persons owning a majority of our outstanding voting securities had approved amendments to our Articles of Incorporation to increase in our authorized capital and provide that the Board of Directors can change the name of our Company without stockholder approval. Our Definitive Information Statement is incorporated herein by reference. See Part III, Item 13. PART II Item 5. Market for Common Equity, Related Stockholder Matters and Small Business Purchases of Equity Securities. ---------------------------------------- Market Information. ------------------- There is no "established trading market" for our shares of common stock. We are listed on the OTC Bulletin Board of the National Association of Securities Dealers, Inc. (the "NASD") under the symbol "LVRO"; however, management does not expect any established trading market to develop unless and until we have material operations. In any event, no assurance can be given that any market for our common stock will develop or be maintained. If a public market ever develops in the future, the sale of "unregistered" and "restricted" shares of common stock pursuant to Rule 144 of the Securities and Exchange Commission by members of management or others may have a substantial adverse impact on any such market. All of these persons have satisfied the one-year holding period requirement of Rule 144. See the heading "Sales of Unregistered Securities During the Past Three Years," of this Annual Report. Set forth below are the high and low closing bid prices for our common stock for each quarter of 2004. These bid prices were obtained from Pink Sheets, LLC, formerly known as the "National Quotation Bureau, LLC," All prices listed herein reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not represent actual transactions. Quotations for our common stock only commenced at the end of the fourth quarter of 2002. Quarter Ended High Bid Low Bid ------------- -------- ------- January 2, 2004 through March 31, 2004 $0.30 $0.20 April 1, 2004 through June 30, 2004 $8.00 $0.25 July 1, 2004 through September 30, 2004 $7.50 $7.50 October 1, 2004 through December 31, 2004 $7.50 $7.50 Holders. -------- The number of record holders of our common stock as of the date of this Annual Report is approximately 1632. This does not include an indeterminate number of stockholders who may hold their shares in "street name." Dividends. ---------- We have not declared any cash dividends with respect to our common stock and do not intend to declare dividends in the foreseeable future. There are no material restrictions limiting, or that are likely to limit, our ability to pay dividends on our common stock. Securities Authorized For Issuance under Equity Compensation Plans. ------------------------------------------------------------------- In March 2003, our Board of Directors approved and adopted the "2003 Stock Option/Stock Issuance Plan" with a maximum of 1,500,000 shares of common stock reserved for issuance under the plan. The Plan provides for both the direct award of shares and for the grant of options to purchase shares. The Board of Directors has authorized options to purchase 500,000 common shares to be granted at a purchase price of $0.01 per share, but to date we have not granted any options to our employees, officers or directors. Under the Plan, the Board of Directors shall determine which eligible persons are to receive Incentive Options, Non-Statutory grants or stock issuances. The Board of Directors also sets the exercise price for options granted. The option terms are not to exceed ten years from the option grant date. At December 31, 2004, total awards available to be granted from the Plan amounted to 1,500,000. Recent Sales of Restricted Securities; Use of Proceeds of Registered Securities. ----------- Resales of Restricted Securities. --------------------------------- For the three years ended December 31, 2004, the following are the only "restricted securities" of our Company that were sold: Name Date Number of shares Consideration ---- ---- ---------------- ------------- Jack R. Coombs 6/01 7,200 $0.25 North Beck 9/01 5,000,000 Mining Lease Various 5/03 25,000 $0.03 Various 5/03 1,915,000 $0.05 Various 6/03 7,875,000 $0.03 Various 6/03 3,750 $0.03 LipidViro-Utah 1/04 213,112 Reorganization We issued all of these securities to persons who were either "accredited investors," or "sophisticated investors" who, by reason of education, business acumen, experience or other factors, were fully capable of evaluating the risks and merits of an investment in our company; and each had prior access to all material information about us. We believe that the offer and sale of these securities were exempt from the registration requirements of the Securities Act, pursuant to Sections 4(2) and 4(6) thereof, and Rule 506 of Regulation D of the Securities and Exchange Commission and from various similar state exemptions. Use of Proceeds of Registered Securities. ----------------------------------------- There were no proceeds received during the calendar year ended December 31, 2004, from the sale of registered securities. Purchases of Equity Securities by Us and Affiliated Purchasers. --------------------------------------------------------------- There were no purchases of our equity securities by us or any affiliated purchasers during the calendar year ended December 31, 2004. Item 6. Management's Discussion and Analysis or Plan of Operation. ---------------------------------------------------------- Overview. --------- We are a development-stage biotechnology company engaged in developing drug products, fluid purification processes, and drug production and delivery systems (DPD System). Utilizing our proprietary DPD System, we are currently developing two products for commercialization; therapeutic treatments for Cardiovascular diseases; and processes to inactivate virus, bacteria and prions producing pathogen-free biological products. Technology. ----------- Our technology is based on three components: * Our proprietary Drug Production and Delivery System (DPD System) which produces and delivers a precise, measured dose of ozone (LTV3); * Our proprietary Gas-Fluid Exchange Device (GFE Device) which efficiently mixes ozone with a fluid; and * Our proprietary methods utilizing precise, measured dosages of ozone in the treatment of disease and purification of bio-fluids. We have applied for patent protection on all aspects of this technology. While medicinal ozone therapies have been used for decades in European countries, the FDA rejected applications to develop ozone as a drug in the United States. The common reason underlying these repeated failures was poor measuring and mixing techniques and the inability to produce and deliver ozone in precise, measured dosages. Our proprietary ozone Drug Production and Delivery System (DPD System) solve both of these problems. The LipidViro DPD System produces a precise, measured dose of ozone, accurate within 2% of the total dose. The technology behind the DPD system allows for a precise, standardized treatment to be delivered by any clinician throughout the world. Our GFE Device efficiently mixes ozone with a fluid by achieving superior surface area contact between the gas and the fluid; and it produces efficient, controlled, consistent, and reproducible mixing, allowing for reliable, repeatable ozone delivery, maximizing treatment results. We believe our technology provides the first and only process able to deliver precise, measured doses of ozone that are consistent and reproducible. We believe this proprietary technology establishes LipidViro as the exclusive market leader, with the only process capable of achieving regulatory approval for use of ozone as a drug. 2004 Pre-Clinical Laboratory Research, Product Development. ----------------------------------------------------------- Equipment Development and Pre-Clinical Research. ------------------------------------------------ During the first fiscal quarter of 2004, we designed, engineered and constructed the first generation of our proprietary drug manufacturing equipment utilized in producing our investigational compound, LVT3. We also engineered and constructed the first ("GEN-1") and second generation ("GEN-2") of our proprietary LVT3 drug delivery systems utilized in our Viral Inactivation Platform. After constructing and testing the equipment, we commenced pre-clinical research of LVT3 with out GEN-2 technology. On March 29, 2004, we released pre-clinical research results of studies that utilized LVT3 and our GEN-2 technology. The results demonstrated substantial inactivation of four different infectious viruses, including: a DNA and a RNA virus, both with simple lipid envelopes; a DNA virus with a complex lipid envelope; and, a small, non-enveloped virus. The research was sponsored by us and conducted by an independent laboratory. The studies were performed in a variety of biological media chosen to represent potential candidates for commercial products. We are encouraged by these results, as a demonstration of antiviral efficacy in four differently structured viruses suggests a broad spectrum antiviral capacity, with the ability to inactivate multiple families of viruses structured similarly to those studied. See our 8-K Current Report dated and filed May 10, 2004, with the Securities and Exchange Commission and which is incorporated herein by reference. See Part III, Item 13. Also during the first quarter, we utilized results from hundreds of studies performed with the GEN-1 and GEN-2 systems to further refine our drug delivery technology and maximize the efficacy of LVT3. As a result of these efforts, late in the first quarter, we completed engineering and construction of our third generation ("GEN-3") drug delivery system. During the second fiscal quarter of 2004, we initiated performance assessment of the newly constructed GEN-3 system, performed studies to further evaluate our Viral Inactivation Platform, initiated a series of toxicity studies and expanded the scope of our research by initiating prion research and developing our Cardiovascular Platform. The viral inactivation studies were designed using infectious virus prepared in artificially contaminated commercial bovine growth serum preparations. The studies compared efficiency and performance to our earlier GEN-2 technology. On May 10, 2004, we announced preliminary results of this research. The studies were conducted on an RNA-based, nucleo-enveloped rhabdovirus, and demonstrated substantial inactivation of the measurable virus in less than half the time required by the older GEN-2 technology. In addition, the studies demonstrated the new GEN-3 system required less than half the dosage of LVT3 required by the earlier GEN-2 system to achieve similar viral inactivation. These improvements in the efficacy of delivering LVT3 are very encouraging for our Viral Inactivation Platform, but also translate directly to all of our disease Platforms, which will also utilize the GEN-3 drug delivery technology. Biological Fluid Purification. ------------------------------ During the third fiscal quarter 2004, we designed studies to examine the effect of LVT3 delivered through our GEN-3 technology on a variety of biological fluids that we are considering for potential commercial development. These studies include the evaluation of protein structure and cellular growth potential, both essential parameters in the maintenance of the integrity of specific commercial products. These studies are ongoing. Prion Research. --------------- During the second fiscal quarter of 2004, our contracted laboratory facilities took part in and passed USDA and state health inspections and applied for and received USDA licensing to purchase and transport infectious prion material. This allowed us to initiate the laboratory research required to investigate the ability of LVT3 to inactivate prions. During the third fiscal quarter of 2004, we designed and performed complex studies which allowed us to identify the presence and quantify amounts of infectious prion proteins in biological media. The results of these studies have allowed us to treat infectious prion proteins in artificially contaminated biological media and determine if we could render it non- infectious. During the fourth fiscal quarter, we treated bovine serum preparations spiked with infectious prion in studies designed to evaluate the ability of our technology to inactivate prions in bovine serum. On March 3, 2005, we announced pre-clinical research results which demonstrated the ability to substantially inactivate infectious prion proteins in bovine serum. Our proprietary technology reduced prion infectivity in bovine serum below the limits of detection in both cell and Western blot assays; two gold standards for prion detection. These data were submitted for presentation at the Meeting of the International Union of Microbiological Societies, San Francisco, July 2005. Cardiovascular Platform. ------------------------ During the second fiscal quarter of 2004, we began development and design of pre-clinical studies associated with our Cardiovascular Platform. During the third fiscal quarter 2004, we engineered and constructed the fourth generation of our proprietary drug delivery technology, the "GEN-4H", designed specifically for use in human trials. The GEN-4H was designed specifically to develop pilot data from human studies using our proprietary technology and our investigational compound LVT3. These data will allow us to evaluate LVT3 and our proprietary drug delivery technology as a commercial therapeutic for the treatment of cardiovascular diseases. During the third and fourth fiscal quarters of 2004, we initiated preliminary in-vitro studies utilizing the new GEN-4H drug delivery system. Theses early studies are designed to evaluate biocompatibility, toxicity and performance for human use. These studies are ongoing. During the fourth fiscal quarter of 2004, we initiated discussions with foreign clinical investigators in an attempt to initiate human trials to treat cardiovascular disease using our proprietary technology. These discussions are ongoing. Intellectual Property. ---------------------- During fiscal year 2003-2004, we filed for patent protection covering our LVT3 drug production and delivery technology and, and our GEN-1, GEN-2 GEN-3 and GEN-4H drug delivery devices, and for proprietary applications utilized by our process. Viral Purification of Biologicals - Background. ----------------------------------------------- The risk of viral and prion contamination is a feature common to all biologicals whose production involves the use of material of animal or human origin. Contamination of a biological may arise from the source material, e.g. cell banks of animal origin, human blood, human or animal tissues, or as adventitious agents introduced by the production process, e.g. the use of animal sera in cell culture. Other examples of products at risk for viral contamination include: * Products derived from in-vitro culture of cell lines of human or animal origin; * Products derived from in-vivo culture of cells or from organs or tissues of human or animal origin; and * Products derived from blood and fractionates thereof, urine or other biological fluids of human or animal origin. Research reports a number of biologicals administered to humans have been contaminated with viruses and prion. In several instances, the transmission of disease due to contamination was only identified many years after the product had been introduced into the market because contamination occurred prior to recognition and understanding of the infectious agent. The primary cause of biological derived disease transmissions has been contamination of the starting or source materials. Viral contamination examples include Yellow Fever vaccine, which was contaminated by avian leucosis virus by virtue of its production in naturally infected hen eggs. SV40 was a contaminant of poliovirus and adenovirus vaccines prepared in the 1950's. These vaccines were developed on primary cultures of kidney cells obtained from Rhesus monkeys which naturally harbored a clinically undetectable infection of SV40. In addition, viruses present in human plasma, e.g., HIV and HCV, have contaminated blood products while human growth hormone extracted from the pituitaries of cadavers and transfusion of blood products have been implicated in the Transmission of the infectious prion protein believed to be responsible for Creutzfeldt-Jacob disease. Validation of Viral Inactivation. --------------------------------- Our pre-clinical research program is designed to investigate the ability of our technology to inactive different viruses, while also considering safety, toxicity and the ability to maintain the integrity of the biological media being studied. Our viral inactivation validation research is designed to: (i) provide evidence that our process will effectively inactivate viruses which are either known to contaminate the starting materials, or which could conceivably do so; and, (ii) provide indirect evidence that our process might inactivate viruses that are presently unknown or undetectable, or for which testing is generally not conducted or is unavailable. Evidence of inactivation is achieved by deliberately adding (spiking) a virus to a biological similar or identical in composition to a biological being considered for development as a commercial product, then measuring for the presence of infectious virus after treatment with our technology. Viral inactivation validation research will assist in demonstrating the capacity and efficacy of our proprietary process to inactivate different viruses. It will also provide an evaluation of the efficacy of our technology to purify certain biological media from infectious viruses which is a product category we are evaluating for commercial development. Virus Research Choices. ----------------------- The viruses selected for study are chosen first to resemble, as closely as possible, viruses which would typically contaminate the biological media being considered, and secondly to represent as wide a range of physico- chemical properties as possible in order to test the ability of the system to eliminate viruses in general. Generally, a process used for purifying biologics of viruses must demonstrate an ability to inactivate a full spectrum of different viruses, including: retroviruses, small and large, lipid enveloped DNA and RNA viruses, and small and large DNA and RNA non-enveloped viruses. Where two similar viruses are available for our viral inactivation studies, either because of their equal resemblance to possible contaminates, or similarities in their properties, it is preferred to study the virus considered to be more resistant. Where available, viruses which can be grown to a high titer (concentration) will be selected, although this may not always be possible. The different viruses chosen to represent the range of viruses we study, require different assay methodologies to demonstrate viral inactivation. These infectivity assays may involve plaque formation, detection of other cytopathic effects such as syncytia or foci formation, end point titrations (e.g. TCID50 assays), detection of virus antigen synthesis or other methods. Generally, the assay method chosen for different viruses will be selected based on a high level of relative sensitivity and reproducibility and will be performed in sufficient replicates and controls to ensure adequate statistical accuracy of the results. 2004 Twelve Month Operational Plan and 2005 Milestones. ------------------------------------------------------- During 2004, we accomplished the following milestones set out one year ago in our operational plan for 2004. Our Operational plan called for further development of our Drug Production and Delivery System; further development of our Gas-Fluid Exchange Devices; testing of the combined system, developing intellectual property covering our technology then identification and selection of products for commercial development. We accomplished these objectives by developing the LipidViro DPD System and four generations of our proprietary Gas-Fluid Exchange Devices. Combined our proprietary technologies produce and deliver a precise, measured dose of ozone, suitable for standardized dosing. Testing on multiple, differently structured viruses demonstrated wide antiviral capacity; studies of infectious prions proteins demonstrate breakthrough inactivation of prions in sera products. Our research identified two products suitable for commercial development, purification of bio-fluids and therapeutic treatments for several cardiovascular diseases. 2005 Milestones and Operational Plan. ------------------------------------- Corporate Development: Our corporate operations objectives for 2005 include financing operations, establishing corporate governance sufficient to apply for NASDAQ SM cap listing, developing and implementing a public relations strategy to enhance shareholder liquidity and value. Scientific Agenda: Our scientific agenda for 2005 includes, site selection and contracting for initial cardiovascular clinical trials; design and initiate cardiovascular clinical trials to produce pilot data; design and initiate Phase I cardiovascular clinical trials; and selection of a strategic partner for sera purification. Technology Development: Our technology agenda for 2005 includes: selecting a strategic partner to produce the LipdiViro Drug Production and Delivery System; and, selecting a strategic partner to manufacture the LipidViro Gas-Fluid Exchange Device. Financing: We require immediate financing to fund operations for the next 12 months, including our described technology and corporate development and our scientific agenda. During fiscal year 2005 we will attempt to raise $3-7 million dollars from equity, debt and grants, which we believe will sufficiently sustain our projected operations through the end of fiscal '06. We will attempt to raise additional money from the exercise of the Company's Class A and B warrants during June of 2006. If fully exercised, these warrants could raise an additional $28 million. We do not have sufficient cash on hand to finance our current plan of operation. Since inception, debt and equity financing have funded all operations including research expenses. We expend and will likely continue to expend substantial funds to complete our research, development and operational objectives. To fund these operations we will consider all options available. Consequently, now and on an ongoing basis we will consider raising capital through collaborative arrangements, strategic alliances, research grants or equity and debt financings or from other sources. Safe Harbor Statement. ---------------------- Statements made in this Form 10-KSB which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of our Company, including, without limitation: (i)our ability to develop products and technologies acceptable to industry; establish and maintain relationships with licensees and other users of our technology and products; and raise capital; (ii) statements preceded by, followed by or that include the words "may", "would", "could", "should", "expects", "projects", "anticipates", "believes", "estimates", "plans", "intends", "targets" or similar expressions. Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our Company's control) that could cause actual results to differ materially from those set forth in the forward- looking statements, including the following, in addition to those contained in our Company's reports on file with the SEC: general economic or industry conditions, nationally and/or in the communities in which our Company conducts business; legislation or regulatory requirements; conditions of the securities markets; the development of products that may be superior to the products developed by our Company; competition; changes in the quality or composition of our Company's products; our ability to develop new products; our ability to raise capital; changes in accounting principals, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors affecting our Company's operations, products, services and prices. Accordingly, results actually achieved may differ materially from expected results in these statements. Forward-looking statements speak only as of the date they are made. Our Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements. Item 7. Consolidated Financial Statements. ---------------------------------- LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2004 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] CONTENTS PAGE Report of registered independent public accounting firm 1 Consolidated Balance Sheet, December 31, 2004 2 Consolidated Statements of Operations, for the Year ended December 31, 2004 and for the period from inception on May 6, 2003 through December 31, 2003 and 2004 3 Consolidated Statement of Stockholders' Equity, from inception on May 6, 2003 through December 31, 2004 4 Consolidated Statements of Cash Flows, for the Year ended December 31, 2004 and for the period from inception on May 6, 2003 through December 31, 2003 and 2004 5 Notes to Consolidated Financial Statements 6 - 15 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors LIPIDVIRO TECH, INC. AND SUBSIDIARY Salt Lake City, Utah We have audited the accompanying consolidated balance sheet of LipidViro Tech, Inc. and Subsidiary [a development stage company] at December 31, 2004 and the related consolidated statements of operations, stockholders' equity and cash flows for the year ended December 31, 2004 and for the periods from inception on May 6, 2003 through December 31, 2003 and 2004. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of LipidViro Tech, Inc. and Subsidiary [a development stage company] as of December 31, 2004 and the consolidated results of their operations and their cash flows for the year ended December 31, 2004 and for the periods from inception on May 6, 2003 through December 31, 2003 and 2004, in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 10 to the financial statements, the Company was only recently formed and has not yet been successful in establishing profitable operations. Further, the Company has current liabilities in excess of current assets. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Management's plans in regards to these matters are also described in Note 10. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. /s/Pritchett, Siler & Hardy PRITCHETT, SILER & HARDY, P.C. Salt Lake City, Utah February 14, 2005 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] CONSOLIDATED BALANCE SHEET ASSETS December 31, 2004 ___________ CURRENT ASSETS: Cash $ - ___________ Total Current Assets - PROPERTY AND EQUIPMENT, net 2,471 OTHER ASSETS: Goodwill 290,318 Other Intangible Assets 29,489 ___________ Total Other Assets 319,807 ----------- Total Assets $ 322,278 =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Bank Overdraft $ 1,023 Accounts payable 159,063 Shareholder advances 202,500 ----------- Total Current Liabilities 362,586 ----------- MINORITY INTEREST IN SUBSIDIARY - COMMITMENTS - STOCKHOLDERS' EQUITY: Common stock, no par value, 150,000,000 shares authorized, 10,031,862 shares issued and outstanding 10,032 Additional paid-in capital 344,352 Deficit accumulated during the development stage (394,692) ----------- Total Stockholders' Equity (40,308) ----------- Total Liabilities and Stockholders' Equity $ 322,278 =========== F-3 The accompanying notes are an integral part of these financial statements. LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] CONSOLIDATED STATEMENTS OF OPERATIONS From Inception For the on May 6, Year ended 2003 Through December 31, December 31, _________________________________ 2004 2003 2004 _________________________________ REVENUE $ $ $ - EXPENSES: General and administrative 73,098 80,157 153,255 Research and development 175,902 65,558 241,460 ---------- ---------- --------- Total Expenses 249,000 145,715 394,715 ---------- ---------- --------- LOSS FROM OPERATIONS (249,000) (145,715) (394,715) OTHER INCOME (EXPENSES): Other Income 23 - 23 ---------- ---------- --------- Total Other Income (Expenses) 23 - 23 ---------- ---------- --------- LOSS BEFORE INCOME TAXES (248,977) (145,715) (394,692) CURRENT TAX EXPENSE - - - DEFERRED TAX EXPENSE - - - ---------- ---------- --------- LOSS BEFORE MINORITY INTEREST MINORITY INTEREST IN SUBSIDIARY'S OPERATIONS (248,977) (145,715) (394,692) MINORITY INTEREST IN SUBSIDIARY'S OPERATIONS - - - ---------- ---------- --------- NET LOSS $ (248,977)$ (145,715) $(394,692) ========== ========== ========= LOSS PER COMMON SHARE $ (.02)$ (.02) $ (.04) ========== ========== ========= F-4 The accompanying notes are an integral part of these financial statements. LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY FROM THE DATE OF INCEPTION ON MAY 6, 2003 THROUGH DECEMBER 31, 2004 Deficit Accumulated Common Stock Additional During the _______________________ Paid-in Development Shares Amount Capital Stage BALANCE, May 6, 2003 - $ - $ - $ - Issuance of 25,000 shares of common stock for payment of organization costs of $750, or $.03 per share, May 2003 25,000 25 725 - Issuance of 1,915,000 units, each consisting of one share of common stock, one class A warrant and one class B warrant, for cash of $95,960, or approximately $.05 per unit, May 2003 1,915,000 1,915 94,045 - Issuance of 7,875,000 shares of Common stock for cash of $236,250, or $.03 per share, June 2003 7,875,000 7,875 228,375 - Issuance of 3,750 shares of common stock for services rendered valued at $113, or $.03 per share, June 2003 3,750 4 109 - Net loss for the period ended December 31, 2003 - - - (145,715) ----------- ----------- -------- ----------- BALANCE, December 31, 2003 9,818,750 $ 9,819 $323,254 $ (145,715) Issuance of 213,112 shares of common stock for the purchase minority interest at $21,311, or $.10 per share, January 2004 213,112 213 21,098 - Net loss for the period ended December 31, 2004 - - - (248,977) ----------- ----------- -------- ----------- BALANCE, December 31, 2004 10,031,862 $ 10,032 $344,352 $ (394,692) =========== =========== ======== =========== F-5 The accompanying notes are an integral part of these financial statements. LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] CONSOLIDATED STATEMENTS OF CASH FLOWS From Inception For the on May 6, Year ended 2003 Through December 31, December 31, ___________________________ 2004 2003 2004 __________________________________________ Cash Flows from Operating Activities: Net loss $ (248,977) $ (145,715) $ (394,692) Adjustments to reconcile net loss to net cash used by operating activities: Depreciation and amortization expense 1,119 185 1,304 Non-cash expenses paid by issuance of common stock 750 750 Non-cash services paid by issuance of common stock 113 113 Changes in assets and liabilities: (Increase) in prepaid expense 3,919 (3,919) Increase in bank overdraft 1,023 1,023 Increase in accounts payable 132,677 26,287 159,064 ---------- ---------- ---------- Net Cash (Used) by Operating Activities (110,239) (122,199) (232,438) ---------- ---------- ---------- Cash Flows from Investing Activities: Payments for property and equipment (960) (2,303) (3,263) Payments for intangible assets (30,003) (30,003) Payments for goodwill (269,006) (269,006) ---------- ---------- ---------- Net Cash (Used) by Investing Activities (30,963) (271,309) (302,272) ---------- ---------- ---------- Cash Flows from Financing Activities: Proceeds from shareholder advances 137,500 65,000 202,500 Proceeds from issuance of common stock 293,700 293,700 Proceeds from sale of warrants 38,510 38,510 ---------- ----------- ----------- Net Cash Provided by Financing Activities 137,500 397,210 534,710 Net Increase (Decrease) in Cash (3,702) 3,702 - Cash at Beginning of Period 3,702 - - ---------- ----------- ----------- Cash at End of Period $ - $ 3,702 $ - ========== =========== =========== Supplemental Disclosures of Cash Flow Information: Cash paid during the period for: Interest $ - $ - $ - Income taxes - - $ - Supplemental Schedule of Non-cash Investing and Financing Activities: For the period from inception on May 6, 2003 through December 31, 2004: In January 2004, the Company issued 213,112 shares of common stock as part of a downstream merger [See Note 2]. In June 2003, the Company issued 3,750 shares of common stock for services rendered valued at $113. In May 2003, the Company issued 25,000 shares of common stock as repayment of organization costs of $750. F-6 The accompanying notes are an integral part of these financial statements. LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization - LipidViro Tech, Inc. ("Parent") was organized under the laws of the State of California on October 19, 1954 as Anticline Uranium, Inc. In October 2001, Parent changed its domicile from California to Nevada by merging with and into a wholly owned subsidiary with the same name and the Nevada entity being the surviving entity. In January 2004, Parent changed its name to LipidViro Tech, Inc. On June 24, 2003, Subsidiary acquired 95.9% of the outstanding stock of Parent pursuant to a Share Purchase Agreement. The agreement called for Subsidiary to pay $65,718 to the former shareholders of Parent for 5,000,000 shares of Parent's common stock wherein Parent became a 95.9% owned subsidiary of Subsidiary [See Note 3]. On January 14, 2004, Parent issued 9,818,750 shares of its common stock for all 9,818,750 outstanding shares of Subsidiary's common stock wherein Subsidiary became a wholly owned subsidiary of Parent in a transaction which has been accounted for as a downstream merger [See Note 2]. Accordingly, the equity transactions have been restated to reflect the recapitalization of Subsidiary and the operations of Parent prior to June 24, 2003 have been eliminated. The financial statements reflect the operations of Subsidiary from its inception. Lipidviro Tech Inc. ("Subsidiary") was organized under the laws of the State of Utah on May 6, 2003. LipidViro Tech, Inc. and Subsidiary ("the Company") plans to research and market substances and compounds for antiviral and antibacterial purposes. The Company has not generated any revenues from their planned principal operations and is considered a development stage company as defined in Statement of Financial Accounting Standards No. 7. The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors. Consolidation - The consolidated financial statements include the accounts of Parent and Parent's 95.9% owned Subsidiary. All significant intercompany transactions have been eliminated in consolidation. Cash and Cash Equivalents - The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents. Property and Equipment - Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of five years. In accordance with Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", the Company periodically reviews their property and equipment for impairment. Website Costs - The Company has adopted the provisions of Emerging Issues Task Force 00-2, "Accounting for Web Site Development Costs." Costs incurred in the planning stage of a website are expensed as research and development while costs incurred in the development stage are capitalized and amortized over the life of the asset, estimated to be five years. As of December 31, 2004 and 2003, the Company had capitalized a total of $2,830 and $1,870 of website costs which are included in property and equipment. The Company did not incur any planning costs and did not record any research and development costs for the period from inception on May 6, 2003 through December 31, 2004. F-7 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued Intangible Assets - The Company accounts for their intangible assets in accordance with Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets". SFAS No. 142 establishes three classifications for intangible assets including definite-life intangible assets, indefinite-life intangible assets and goodwill and requires different accounting treatment and disclosures for each classification. In accordance with SFAS No. 142, the Company periodically reviews their intangible assets for impairment. No impairment was recorded during the period from inception on May 6, 2003 through December 31, 2004. Research and Development - Research and development costs are expensed as incurred. The Company expensed $175,902 and $65,558 in research and development costs during the year ended December 31, 2004 and the period from inception on May 6, 2003 through December 31, 2003, respectively. Minority Interest - From June 24, 2003 through January 14, 2004, Subsidiary owned 95.9% of Parent. The net loss of Parent applicable to the non- controlling minority interest was not allocated to the minority interests as there was no obligation of the non-controlling minority interests to share in such losses. On January 14, 2004, Subsidiary acquired the minority interest in a downstream merger [See Note 2]. Loss Per Share - The computation of loss per share is based on the weighted average number of shares outstanding during the period presented in accordance with Statement of Financial Accounting Standards No. 128, "Earnings Per Share" [See Note 11]. Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimated. Recently Enacted Accounting Standards - In January 2003, the Emerging Issues Task Force ("EITF") issued EITF Issue No. 00-21, Accounting for Revenue Arrangements with Multiple Deliverables. This consensus addresses certain aspects of accounting by a vendor for arrangements under which it will perform multiple revenue-generating activities, specifically, how to determine whether an arrangement involving multiple deliverables contains more than one unit of accounting. EITF Issue No. 00-21 is effective for revenue arrangements entered into in fiscal periods beginning after June 15, 2003, or entities may elect to report the change in accounting as a cumulative-effect adjustment. The adoption of EITF Issue No. 00-21 did not have a material impact on the Company's financial statements. In January 2003, the FASB issued Interpretation ("FIN") No. 46, Consolidation of Variable Interest Entities. Until this interpretation, a company generally included another entity in its consolidated financial statements only if it controlled the entity through voting interests. FIN No. 46 requires a variable interest entity, as defined, to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns. FIN No. 46 is effective for reporting periods ending after F-11 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued Recently Enacted Accounting Standards (continued) December 15, 2003. The adoption of FIN No. 46 did not have an impact on the Company's financial statements. In April 2003, the FASB issued SFAS No. 149, Amendment of Statement 133 on Derivative Instruments and Hedging Activities, which amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133. SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. The adoption of SFAS No. 149 will not have an impact on the Company's financial statements. In May 2003, the FASB issued SFAS No. 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS No. 150 changes the accounting guidance for certain financial instruments that, under previous guidance, could be classified as equity or "mezzanine" equity by now requiring those instruments to be reported as liabilities. SFAS No. 150 also requires disclosure relating to the terms of those instruments and settlement alternatives. SFAS No. 150 is generally effective for all financial instruments entered into or modified after May 31, 2003, and is otherwise effective at the beginning of the first interim period beginning after June 15, 2003. The adoption of SFAS No. 150 did not have an impact on the Company's financial statements. In December 2003, the SEC issued SAB No. 104. SAB No. 104 revises or rescinds portions of the interpretative guidance included in Topic 13 of the codification of staff accounting bulletins in order to make this interpretive guidance consistent with current authoritative accounting and auditing guidance and SEC rules and regulations. It also rescinds the Revenue Recognition in Financial Statements Frequently Asked Questions and Answers document issued in conjunction with Topic 13. Selected portions of that document have been incorporated into Topic 13. The adoption of SAB No. 104 in December 2003 did not have an impact on the Company's financial position, results of operations or cash flows. In November 2004, the FASB issued SFAS No. 151, Inventory Costs. This statement amends the guidance in ARB No. 43, Chapter 4, Inventory Pricing, to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage). In addition, this Statement requires that allocation of fixed production overheads to the costs of conversion be based on the normal capacity of the production facilities. The adoption of SFAS No. 151 did not have an impact on the Company's consolidated financial statements. In December 2004, the FASB issues SFAS No. 152, Accounting for Real Estate Time-Sharing Transactions. This Statement amends FASB Statement No. 66, Accounting for Sales of Real Estate, to reference the financial accounting and reporting guidance for real estate time-sharing transactions that is provided in AICPA Statement of Position (SOP) 04-2, Accounting for Real Estate Time-Sharing Transactions. This Statement also amends FASB Statement No. 67, Accounting for Costs and Initial Rental Operations of Real Estate Projects, to state that the F-12 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued Recently Enacted Accounting Standards (continued) guidance for (a) incidental operations and (b) costs incurred to sell real estate projects does not apply to real estate time-sharing transactions. The accounting for those operations and costs is subject to the guidance in SOP 04-2. This Statement is effective for financial statements for fiscal years beginning after June 15, 2005. The adoption of SFAS No. 152 did not have an impact on the Company's consolidated financial statements. In December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary Assets. The guidance in APB Opinion No. 29, Accounting for Nonmonetary Transactions, is based on the principle that exchanges of nonmonetary assets should be measured based on the fair value of the assets exchanged. This Statement amends Opinion 29 to eliminate the exception for nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. A nonmonetary exchange has commercial substance if the future cash flows of the entity are expected to change significantly as a result of the exchange. The adoption of SFAS No. 153 did not have an impact on the Company's consolidated financial statements. In December 2004, the FASB issued SFAS No. 123, Summary of Statement No. 123 (revised 2004). This Statement is a revision of FASB Statement No. 123, Accounting for Stock-Based Compensation. This Statement supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and its related implementation guidance. This Statement establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. This Statement focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. This Statement does not change the accounting guidance for share-based payment transactions with parties other than employees provided in Statement 123 as originally issued and EITF Issue No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services. The Company is currently evaluating the provisions of SFAS 123 and the impact that it will have on its share based employee compensation programs. Restatement - The financial statements have been restated for all periods presented to reflect the recapitalization of Subsidiary [See Note 2] and to reflect a 1-for-100 reverse stock split that Parent effected on October 4, 2001 and a 4-for-1 forward stock split that Parent effected on December 31, 2001 [See Note 7]. F-12 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - DOWNSTREAM MERGER On January 14, 2004, Subsidiary acquired the minority interests in Parent and Subsidiary was reorganized as a subsidiary of Parent in a transaction in which Parent issued 9,818,750 shares of its common stock in exchange for all 9,818,750 outstanding shares of Subsidiary's common stock. Accordingly, the equity transactions have been restated to reflect the recapitalization of Subsidiary. The Company recorded goodwill of $21,311 as a result of the downstream merger. The financial statements reflect the operations of Subsidiary from its inception. As part of the downstream merger, Parent issued 1,915,000 Class A warrants and 1,915,000 Class B warrants to replace similar warrants of Subsidiary. Parent also cancelled 5,000,000 shares of its common stock which had previously been owned by Subsidiary. NOTE 3 - ACQUISITION OF 95.9% OF LIPIDVIRO TECH, INC. On June 24, 2003, Subsidiary acquired 95.9% of the outstanding stock of Parent pursuant to a Share Purchase Agreement. The agreement called for Subsidiary to pay $65,718 to the former shareholders of Parent for 5,000,000 shares of Parent's common stock wherein Parent became a 95.9% owned subsidiary of Subsidiary. The agreement also called for Subsidiary to advance an additional $203,282 to pay costs associated with the acquisition and to reduce the liabilities of Parent. The acquisition closed June 24, 2003 and has been accounted for as a purchase of Parent. The Company recorded goodwill of $290,317 as a result of the acquisition. The financial statements reflect the operations of Parent from June 24, 2003. NOTE 4 - PROPERTY AND EQUIPMENT Property and equipment consisted of the following at: December 31, December 31, 2004 2003 ___________ ___________ Office equipment $ 433 $ 433 Website 2,828 1,870 ___________ ___________ 3,261 2,303 Less: accumulated depreciation (790) (185) ___________ ___________ Net property and equipment $ 2,471 $ 2,118 ___________ ___________ Depreciation expense for the years ended December 31, 2004 and 2003 was $605 and $185, respectively. F-13 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 5 - DEFINITE-LIFE INTANGIBLE ASSETS Definite-life intangible assets consist of the following at: December 31, December 31, 2004 2003 ___________ ___________ Pending Patents $ 29,233 $ - Patent applications in process 770 - ----------- ----------- 30,003 - Less: Accumulated amortization (514) - ___________ ___________ Net Definite-life Intangible Assets $ 29,489 $ - ___________ ___________ The Company's definite-life intangible assets are amortized, upon being placed in service, over the estimated useful lives of the assets of 20 years with no residual value. Amortization expense for the year ended December 31, 2004 and for the period from inception on May 6, 2003 through December 31, 2003 was $514 and $0, respectively. The Company estimates that their amortization expense for each of the next five years will be approximately $1,000 per year. NOTE 6 - GOODWILL The Company has no indefinite-life intangible assets. The following is a summary of the transactions affecting the Company's goodwill. December 31, ________________________ 2004 2003 ___________ ___________ Goodwill at beginning of period $ 269,006 $ - Goodwill from the acquisition of 95.9% of Parent - 269,006 Goodwill from the acquisition of the minority interests in Parent 21,311 - ___________ ___________ Goodwill at end of period $ 290,317 $ 269,006 ___________ ___________ F-14 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 7 - CAPITAL STOCK Common Stock - The Company has authorized 150,000,000 shares of common stock with a par value of $.001. In January 2004, the Company issued 213,112 shares of their previously authorized but unissued common stock to the former shareholders of Subsidiary as part of a downstream merger [See Note 2]. In June 2003, the Company issued 3,750 shares of their previously authorized but unissued common stock to an officer of the Company for services rendered valued at $113, or $.03 per share. In June 2003, the Company issued 7,875,000 shares of their previously authorized but unissued common stock for cash of $236,250, or .03 per share. In May 2003, the Company issued 1,915,000 units. Each unit consisted of one share of the Company's previously authorized but unissued common stock, one Class A warrant and one Class B warrant. The units were issued for cash of $95,960, or approximately $.05 per unit. In May 2003, in connection with their organization, the Company issued 25,000 shares of their previously authorized but unissued common stock to an officer of the Company as repayment of organization costs of $750, or $.03 per share. Stock Splits - On December 31, 2001, Parent effected a 4-for-1 forward stock split. On October 4, 2001, Parent effected a 1-for-100 reverse stock split. The financial statements for all periods presented have been restated to reflect these stock splits. Class A Warrants - In May 2003, the Company issued 1,915,000 Class A Warrants for cash of $19,255, or approximately $.01 per warrant, as part of a private placement offering. The warrants vested immediately and are exercisable at $5.00 per share. The warrants were originally exercisable for two years. In August 2003, the Company changed the exercise period so the warrants are only exercisable during June 2006. At December 31, 2004, none of these warrants had been exercised, forfeited or cancelled. Class B Warrants - In May 2003, the Company issued 1,915,000 Class B Warrants for cash of $19,255, or approximately $.01 per warrant, as part of a private placement offering. The warrants vested immediately and are exercisable at $10.00 per share. The warrants were originally exercisable for two years. In August 2003, the Company changed the exercise period so the warrants are only exercisable during June 2006. At December 31, 2004, none of these warrants had been exercised, forfeited or cancelled. Stock Option Plan - In March 2003, the Board of Directors of Parent approved and adopted the "2003 Stock Option/Stock Issuance Plan" ("the Plan") with a maximum of 1,500,000 shares of common stock reserved for issuance under the Plan. The Plan provides for both the direct award of shares and for the grant of options to purchase shares. The Board of Directors has authorized options to purchase 500,000 common shares to be granted at a purchase price of $0.01 per share, but to date the Company has not granted any options to their employees, officers or directors. Under the Plan, the Board of Directors shall determine which eligible persons are to receive Incentive Options, Non-Statutory grants or stock issuances. The Board of Directors also sets the exercise price for options granted. The option terms are not to exceed ten years from the F-15 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Stock Option Plan (continued) option grant date. At December 31, 2004, total awards available to be granted from the Plan amounted to 1,500,000. NOTE 8 - INCOME TAXES The Company accounts for income taxes in accordance with Statement of Financial Accounting Standards No. 109 "Accounting for Income Taxes". SFAS No. 109 requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. The Company has available at December 31, 2004 unused operating loss carryforwards of approximately $480,000 which may be applied against future taxable income and which expire in various years through 2024. Due to substantial changes in the Company's ownership, there will be an annual limitation on the amount of net operating loss carryforwards which can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the deferred tax assets, the Company has established a valuation allowance equal to the tax effect of the loss carryforwards, therefore, no deferred tax asset has been recognized. The net deferred tax assets, which consist of difference in book and tax basis of fixed assets and net operating losses, are approximately $88,350 and $38,400 as of December 31, 2004 and December 31, 2003, respectively, with an offsetting valuation allowance of the same amount, resulting in a change in the valuation allowance of approximately $49,950 during the year ended December 31, 2004. NOTE 9 - RELATED PARTY TRANSACTIONS Management Compensation - The Company has not paid any cash compensation to any officer or director of the Company. However, in June 2003, the Company issued 3,750 shares of common stock to an officer of the Company for services rendered valued at $113 [See Note 7]. Office Space - The Company has not had a need to rent office space. A shareholder (former officer) of the Company is allowing the Company to use her mailing address, as needed, at no expense to the Company. Stock Issuance - In May 2003, in connection with their organization, the Company issued 25,000 shares of their previously authorized but unissued common stock to an officer of the Company as repayment of organization costs of $750, or $.03 per share. Shareholder Advances - During the year ended December 31, 2004, a shareholder of the Company advanced $137,500 to the Company. At December 31, 2004, the Company owes a total of $202,500 to the shareholder. The advances bear no interest and are due December 31, 2005. F-15 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 10 - GOING CONCERN The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company was only recently formed and has not yet been successful in establishing profitable operations. Further, the Company has current liabilities in excess of current assets. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of their common stock. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. NOTE 11 - LOSS PER SHARE The following data shows the amounts used in computing loss per share: From Inception For the on May 6, Year ended 2003 Through December 31, December 31, _________________________________ 2004 2003 2004 _________ _________ _________ Loss from continuing operations available to common shareholders (numerator) $(248,977) $(394,692) $(145,715) Weighted average number of common shares outstanding used in loss per share for the period (denominator) 10,023,710 9,435,941 8,535,842 At December 31, 2004, the Company had 1,915,000 Class A warrants and 1,915,000 Class B warrants outstanding which were not used in the computation of dilutive loss per share because their effect would be anti-dilutive. Dilutive loss per share was not presented, as the Company had no common stock equivalent shares for all periods presented that would effect the computation of diluted loss per share. F-16 LIPIDVIRO TECH, INC. AND SUBSIDIARY [A Development Stage Company] NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 12 - COMMITMENTS AND CONTINGENCIES Agreements - In August 2004, the Company signed a one-year agreement for the use of a research facility and staff to conduct research on behalf of the Company and to have a researcher coordinate the activities. The Company agreed to pay up to $600,000 for supplies, facilities, a laboratory technician and coordination efforts. During the year ended December 31, 2004, the Company paid $5,000 under this agreement. In July 2004, the Company signed a six-month agreement for a researcher to conduct research on behalf of the Company. The Company agreed to pay $15,000 for the services of the researcher. During the year ended December 31, 2004 the Company paid $10,000 under this agreement. In October 2003, the Company signed one-year agreements for the use of a research facility and staff to conduct research on behalf of the Company and to have a researcher coordinate the activities. The Company agreed to pay up to $76,325 for supplies, facilities, a laboratory technician and coordination efforts. The costs incurred under this agreement totaled $75,000. During the year ended December 31, 2004 and the period from inception on May 6, 2003 through December 31, 2003, respectively, the Company paid $52,000 and $23,000 under these agreements. Possible Claims Related to Previously Leased Mining Property - In August 2001, Parent obtained 96.5% of the rights to certain mining claims in the Tintic Mining District of Juab County, Utah under the terms of a 5-year Mining Lease. Under the terms of the lease, Parent was obligated to spend $15,000 over the term of the lease for exploration, mining, development or similar costs for the benefit of the property subject to the lease. Parent was also obligated to pay a 3.5% net smelter royalty on all mineral-bearing ores sold. The lease also gave a credit to Parent for the first $30,000 of net smelter royalties. The lessor also agreed to indemnify and hold Parent harmless from any Environmental Protection Agency claim or claims by a similar state agency based solely on past mining contaminations or other environmental violations or damage. In June 2003, Parent paid $3,459 to cancel the Mining Lease. The Company's management believes that the Company would not be responsible for any future claims against the property which Parent previously leased, but the possibility exists that claims may arise against the property and the Company may be named in such claims based on the previous leasing arrangements. The Company's management believes that the Company would be successful in defending against any such claims that may arise. No accrual for possible losses or settlements has been recorded in the accompanying financial statements. F-17 Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. --------------------- None; not applicable. Item 8(a). Controls and Procedures. ------------------------ As of the end of the period covered by this Annual Report, we carried out an evaluation, under the supervision and with the participation of our President and Chief Operating Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our President and Chief Operating Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be included in our periodic Securities and Exchange Commission reports. It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. In addition, we reviewed our internal controls, and there have been no significant changes in our internal controls or in other factors that could significantly affect those controls subsequent to the date of their last evaluation. Item 8(b) Other Information. ---------------------------- None. PART III Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act. -------------------------------------------------- Identification of Directors and Executive Officers. --------------------------------------------------- The following table sets forth the names of all of our current directors and executive officers for the calendar year ended December 31, 2004, and to the date hereof. These persons will serve until the next annual meeting of the stockholders or until their successors are elected or appointed and qualified, or their prior resignation or termination. Date of Date of Positions Election or Termination Name Held Designation or Resignation ---- ---- ----------- --------------- Kenneth P. Hamik President and 6/24/2003 * Director 6/24/2003 * Kristy Hamik COO and 6/24/2003 1/19/2004 Director 6/24/2003 1/19/2004 Patrick A. Seymour COO and 1/19/2004 4/5/2004 Director 1/19/2004 4/5/2004 * Still are serving in these positions. Directors are elected by our stockholders to serve until the next annual meeting of our stockholders or until their successors have been elected and have been duly qualified. Officers are appointed to serve until the annual meeting of our Board of Directors following the next annual meeting of our stockholders and until their successors have been elected and have qualified. Business Experience. -------------------- Kenneth P. Hamik, President, CEO and a director. Mr. Hamik is 46 years of age. Kenneth P. Hamik has over 20 years of management and consulting experience across a wide range of markets: healthcare, media/entertainment, consumer products, Internet, education, financial services, telecommunications, energy, electronics/computers, air travel and auto manufacturing. He was featured in the January 2000 cover article of Consumer Reports on future product trends, in an MSN article on future career paths, and recently headed a team to manage Charles Schwab electronic relationship management strategies. Before joining LipidViro, he served as Vice President of Marketing & Strategy at Triple Aught, Inc., a Berkeley, California based energy technology & engineering start-up company. Ken completed his Masters of Science work at the University of Houston's Studies of the Future program. He also has a B.S. Degree from the University of Nebraska. Significant Employees. ---------------------- We have no employees who are not executive officers, but who are expected to make a significant contribution to its business. Family Relationships. --------------------- None; not applicable. Involvement in Certain Legal Proceedings. ----------------------------------------- During the past five years, no director, person nominated to become a director, executive officer, promoter or control person of our Company: (1) was a general partner or executive officer of any business against which any bankruptcy petition was filed, either at the time of the bankruptcy or two years prior to that time; (2) was convicted in a criminal proceeding or named subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) was subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or (4) was found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated. Compliance with Section 16(a) of the Exchange Act. -------------------------------------------------- On June 26, 2003, LipidViro-Utah filed a Form 3, Initial Statement of Beneficial Ownership of Securities with the Securities and Exchange Commission regarding their acquisition of 5,000,000 of our shares. On April 20, 2004, LipidViro filed a Form 4, Statement of Changes in Beneficial Ownership of Securities with the Securities and Exchange Commission regarding the return to treasury of 5,000,000 shares after approval at a Fairness Hearing January 12, 2004. Audit Committee. ---------------- We have do not have an Audit Committee due to the fact that we are a development stage company with limited operations that has generated no revenues from operations; however, when operations require, we will designate an Audit Committee. Code of Ethics. --------------- We have adopted a Code of Ethics for our President and Chief Executive Officer that was attached to our 2003 Annual Report on Form 10-KSB as exhibit 14. See Part III Item 13. Item 10. Executive Compensation. ----------------------- In March, 2003, the Board of Directors approved and adopted the "2003 Stock Option/Stock Issuance Plan" ("the Plan") with a maximum of 1,500,000 shares of common stock reserved for issuance under the Plan. The Plan provides for both the direct award of shares and for the grant of options to purchase shares. The Board of Directors has authorized options to purchase 500,000 common shares to be granted at a purchase price of $0.01 per share, but to date our Company has not granted any options to its employees, officers or directors. Under the Plan, the Board of Directors shall determine which eligible persons are to receive Incentive Options, Non-Statutory grants or stock issuances. The Board of Directors also sets the exercise price for options granted. The option terms are not to exceed ten years from the option grant date. At December 31, 2004, total awards available to be granted from the Plan amounted to 1,500,000. Options/SAR Grants in Last Fiscal Year -------------------------------------- Individual Grants ----------------- (a) (b) (c) (d) (e) Number of % of Total Securities Options/SARs Underlying Granted to Options/SARs Employees in Exercise or Base Expiration Name Granted (#) Fiscal Year Price ($/Sh) Date ---- ----------- ----------- ------------ ---- None -0- -0- -0- -0- Compensation of Directors. -------------------------- There are no standard arrangements pursuant to which our directors are compensated for any services provided as a director. No additional amounts are payable to our directors for committee participation or special assignments. Employment Contracts and Termination of Employment and Change-in-Control Arrangements. ------------- There are no employment contracts, compensatory plans or arrangements, including payments to be received from us, with respect to any director or executive officer of ours that would in any way result in payments to any such person because of his or her resignation, retirement or other termination of employment with us or any subsidiary or any change in control of our Company. Item 11. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. ---------------------------- Security Ownership of Certain Beneficial Owners. ------------------------------------------------ The following table sets forth the share holdings of those persons who beneficially own more than five percent of our common stock as of the date of December 31, 2004: Number of Shares Percentage Name and Address Beneficially Owned of Class ---------------- ------------------ -------- Lombard, Inc. 7,875,000 78.5% Blackfriars Limited 568,000 5.7% Security Ownership of Management. --------------------------------- The following table sets forth the shareholdings of our directors and executive officers as of the date of this Report: Number of Percentage of Name and Address Shares Beneficially Owned of Class ---------------- ------------------------- -------- Kenneth P. Hamik 3,750 * All Directors and Executive Officers as a group 3,750 * * Represents less than one percent. Changes in Control. ------------------- To the knowledge of our management, there are no present arrangements or pledges of our securities which may result in a change in control of our Company. Item 12. Certain Relationships and Related Transactions. ----------------------------------------------- Transactions with Management and Others. ---------------------------------------- Except as indicated below, during the calendar years ended December 31, 2004 and 2003, and since then, there were no material transactions, series of similar transactions, currently proposed transactions, or series of similar transactions, to which we or any of our subsidiaries was or is to be a party, in which the amount involved exceeded $60,000 and in which any director or executive officer, or any security holder who is known to us to own of record or beneficially more than five percent of our common stock, or any member of the immediate family of any of the foregoing persons, had a material interest. During the year ended December 31, 2004, a shareholder of our Company advanced $137,500 to us. At December 31, 2004, we owed a total of $202,500 to that shareholder. The advances bear no interest and are due December 31, 2005. Certain Business Relationships. ------------------------------- Except as indicated under the heading "Transactions with Management and Others," during the calendar years ended December 31, 2004 and 2003, and since then, there were no material transactions, series of similar transactions, currently proposed transactions, or series of similar transactions, to which we or any of our subsidiaries was or is to be a party, in which the amount involved exceeded $60,000 and in which any director or executive officer, or any security holder who is known to us to own of record or beneficially more than five percent of our common stock, or any member of the immediate family of any of the foregoing persons, had a material interest. Indebtedness of Management. --------------------------- Except as indicated under the heading "Transactions with Management and Others," during the calendar years ended December 31, 2004 and 2003, there were no material transactions, series of similar transactions, currently proposed transactions, or series of similar transactions, to which we or any of our subsidiaries was or is to be a party, in which the amount involved exceeded $60,000 and in which any director or executive officer, or any security holder who is known to us to own of record or beneficially more than five percent of our common stock, or any member of the immediate family of any of the foregoing persons, had a material interest. Parents of the Issuer. ---------------------- None; not applicable. Transactions with Promoters. ---------------------------- Except as indicated under the heading "Transactions with Management and Others," during the calendar years ended December 31, 2004 and 2003, there were no material transactions, series of similar transactions, currently proposed transactions, or series of similar transactions, to which we or any of our subsidiaries was or is to be a party, in which the amount involved exceeded $60,000 and in which any promoter or founder of us, or any member of the immediate family of any of the foregoing persons, had a material interest. Item 13. Exhibits and Reports on Form 8-K. --------------------------------- Reports on Form 8-K.* --------------------- 8-KA-1 Current Report dated August 19, 2003, regarding the Fairness Hearing on the Reorganization Agreement with LipidViro-Utah, filed with the Securities and Exchange Commission on March 26, 2004.* 8-K Current Report dated March 30, 2004, regarding a press release on results of pre-clinical research.* 8-K Current Report dated May 10, 2004, Introducing the Company's new GEN-3 technology, and reports enhanced viral inactivation utilizing the new GEN-3 technology.* 8-K Current Report dated February 1, 2005, regarding a Press Release and Investor Presentation.* 8-K Current Report dated March 3, 2005, regarding a Press Release.* Exhibits.* ---------- Exhibit Number Description ------ ----------- 31.1 302 Certification of Kenneth P. Hamik 32 906 Certification 10-KSB Annual Report for the year ended December 31, 2004.* Definitive Information Statement filed July 23, 2003.* * The 8-K Current Reports referenced above under this Item, the 10-KSB Annual Report for the year ended December 31, 2004, are incorporated herein by reference in Part I, Item 1, and the Definitive Information Statement is incorporated herein by reference in Part I, Item 4. Item 14. Principal Accountant Fees and Services. --------------------------------------- The following is a summary of the fees billed to LipidViro by its principal accountants during the calendar years ended December 31, 2004, and December 31, 2003: Fee category 2004 2003 ------------ ---- ---- Audit fees $11,629 $6,486 Audit-related fees $ 0 $ 0 Tax fees $ 1,562 $ 110 All other fees $ 0 $ 0 Total fees $13,191 $6,596 Audit fees. Consists of fees for professional services rendered by our principal accountants for the audit of our annual financial statements and the review of financial statements included in our Forms 10-QSB or services that are normally provided by our principal accountants in connection with statutory and regulatory filings or engagements. Audit-related fees. Consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported under "Audit fees." Tax fees. Consists of fees for professional services rendered by our principal accountants for tax compliance, tax advice and tax planning. All other fees. Consists of fees for products and services provided by our principal accountants, other than the services reported under "Audit fees," "Audit-related fees" and "Tax fees" above. SIGNATURES In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LIPIDVIRO TECH, INC. Date: 4/14/05 By/s/Kenneth P. Hamik ------------- ------------------- Kenneth P. Hamik President, Chief Executive Office and Director In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated: Date: 4/14/05 By/s/Kenneth P. Hamik ------------- ---------------------- Kenneth P. Hamik President, Chief Executive Officer and Director